Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study

World Journal of Gastroenterology

Volumn 15, Issue 6, 2009, Pages 713-716

  Edeline, Julien ^a   Raoul, Jean Luc ^a,c   Vauleon, Elodie ^a,c   Guillygomac'h, Anne ^b   Boudjema, Karim ^b,c   Boucher, Eveline ^a  

^a CENTRE EUGÈNE MARQUIS   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c European University in Brittany   (France)

Author keywords

Antineoplastic protocols; Chemotherapy; Hepatocellular carcinoma

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER RESECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; THORAX PAIN; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; SURVIVOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG TOLERANCE; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 65649102210     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.713     Document Type: Article

References (18)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
3. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538
4. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069-3075
5. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-1666
6. Fardel O, Loyer P, Lecureur V, Glaise D, Guillouzo A. Constitutive expression of functional P-glycoprotein in rat hepatoma cells. Eur J Biochem 1994; 219: 521-528
7. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004; 53: 519-526
8. Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, Hayasaka A, Kondo F, Sugiura N, Saisho H. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 2004; 39: 1196-1201
9. Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, Watson M, Hill AS, Nicolson MC, O'Brien ME, Evans TC, Nicolson V. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer 1996; 77: 1978-1985
10. Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM, Park DK, Park YH, Shin DB, Lee JH. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 2005; 68: 333-340
11. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
12. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390
13. Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007; 97: 862-867
14. Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini S, Salmaso F, Mattiazzi M, Sanavio C, Farinati F, Zanus G, Cillo U. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 2006; 17 Suppl 5: v153-v157
15. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6: 3
16. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681
17. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50: 305-308
18. Abou-Alfa GK, Johnson P, Knox J, Lacava J, Leung T, Mori A. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. ECCO 14, Abst 3500, Barcelona, 23-27 September 2007